Insider · CIK 0001992595
Joshua Pinto
directorpresidentofficer
Files at NMRA (Neumora Therapeutics, Inc.), MTSR (Metsera, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 13, 2025 | MTSR Metsera, Inc. | DDisposition to issuer Common Stock | -2,688 | - | - | 0 | Nov 13, 2025 |
| Nov 13, 2025 | MTSR Metsera, Inc. | AGrant or award Restricted Stock Unitderivative | +2,688 | - | - | 2,688 | Nov 13, 2025 |
| Nov 13, 2025 | MTSR Metsera, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -16,125 | - | - | 0 | Nov 13, 2025 |
| Nov 13, 2025 | MTSR Metsera, Inc. | DDisposition to issuer Stock Option (right to buy)derivativeindirect: By LLC | -148,953 | - | - | 0 | Nov 13, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -223,034 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -270,828 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -223,034 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -720,084 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -127,448 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -170,000 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,000,000 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +223,034 | - | - | 223,034 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +270,828 | - | - | 270,828 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +223,034 | - | - | 223,034 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +720,084 | - | - | 720,084 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +127,448 | - | - | 127,448 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +170,000 | - | - | 170,000 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,000,000 | - | - | 3,000,000 | May 30, 2025 |
| May 21, 2025 | NMRA Neumora Therapeutics, Inc. | GGift Common Stock | -13,202 | $0.00 | $0 | 63,750 | May 23, 2025 |
| May 21, 2025 | NMRA Neumora Therapeutics, Inc. | GGift Common Stockindirect: See footnote | +13,202 | $0.00 | $0 | 152,167 | May 23, 2025 |
| May 20, 2025 | MTSR Metsera, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,125 | $0.00 | $0 | 16,125 | May 22, 2025 |
| May 22, 2025 | MTSR Metsera, Inc. | GGift Stock Option (Right to Buy)derivative | -148,953 | $0.00 | $0 | 0 | May 22, 2025 |
| May 22, 2025 | MTSR Metsera, Inc. | GGift Stock Option (Right to Buy)derivativeindirect: By LLC | +148,953 | $0.00 | $0 | 148,953 | May 22, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.